Treatment Information

Back

Liver Cancer treatment details. Chemotherapy.

Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, Massachusetts
Treatments:ChemotherapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Jun 2002

Description:

Patients: This Phase II study involved 30 patients with measurable, unresectable, or metastatic hepatocellular (liver) carcinoma.

Treatment: Treatment consisted of the chemotherapy drug gemcitabine.

Toxicity: Fourteen patients experienced grade 3-4 neutropenia. One patient experienced Grade 3 thrombocytopenia. Other toxicities included nausea/vomiting (grade 2-3) and fatigue (grade 2).

Results: The median survival period was 6.9 months.

Support: The study was supported by Eli Lilly, Inc. Eli Lilly markets gemcitabine.

Correspondence: Charles S. Fuchs, MD





Back